Abatacept: A novel treatment for moderate-to-severe rheumatoid arthritis

Pharmacotherapy

Volumn 27, Issue 12 I, 2007, Pages 1693-1701

  Reynolds, Jennifer ^a   Shojania, Kam ^a   Marra, Carlo A ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Abatacept; Rheumatoid arthritis; Selective costimulation modulators

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ASTHMA; BASAL CELL CARCINOMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; MONOTHERAPY; NAUSEA; NEOPLASM; OUTCOME ASSESSMENT; PATHOGENESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SQUAMOUS CELL CARCINOMA; SYNOVITIS; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; HUMANS; IMMUNOCONJUGATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 36849053798     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.12.1693     Document Type: Review

References (27)

1. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.
2. American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
3. Voll RE, Kalden JR. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann N Y Acad Sci 2005;1051:799-810.
4. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a co-stimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-80.
5. Bristol-Myers Squibb. Orencia (abatacept) product monograph. Princeton, NJ; 2006.
6. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
7. Nadler S, Townsend R, Mikesell G. Abatacept (CTLA4Ig; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations [abstract]. Ann Rheum Dis 2004;63(suppl 1):142.
8. Moreland LW, Alten R, Van den Bosch F, et al. Co-stimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
9. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
10. Kremer J, Dougados MD, Emery P, et al. Treatment of rheumatoid arthritis by the selective co-stimulation modulator abatacept: 12-month results of a phase II study. Arthritis Rheum. 2005;349:1907-15.
11. Weinblatt ME, Schiff MG, Goldman A, et al. Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized-controlled trial. Ann Rheum Dis 2007;66:228-34.
12. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med 2006;144:865-76.
13. Genovese M, Becker J-C, Schiff M, et al. Abatacept (CTLA4Ig) in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor-α inhibitors. N Engl J Med 2005;353:1114-23.
14. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective co-stimulation modulator abatacept in the rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs. Arthritis Rheum 2006:54:2807-16.
15. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
16. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
17. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
18. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70.
19. Ethgen O, Kahler KH, Kong SX, Reginster JY, Wolfe F. The effect of health-related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol 2002;29:1147-55.
20. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983;26:1346-53.
21. Uhlig T, Haavardsholm EA, Kvien TK. Comparison of the health assessment questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. Rheumatol 2006;45:454-8.
22. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006;33:681-9.
23. Haraoui B, Russell A, Zhou Y, et al. Abatacept induces sustained improvements in physical function and pain over 3 years in rheumatoid arthritis patients with inadequate responses to methotrexate [abstract]. J Rheumatol 2006;33:394-5.
24. Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate therapy. Ann Rheum Dis 2007;66:189-94.
25. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology 2006;45:1238-46.
26. Moreland L, Kaine J, Espinoze L, et al. Safety of abatacept in rheumatoid arthritis patients in five double-blind, placebo controlled trials. Presented at the 70th annual scientific meeting of the American College of Rheumatology, San Diego, CA, November 12-17, 2005.
27. Pineda C, Combe B, Covucci A, et al. Abatacept for the treatment of rheumatoid arthritis patients receiving background disease-modifying antirheumatic drugs (DMARDs): safety and patient-reported outcomes from the ASSURE trial [abstract]. J Rheumatol 2006;33:397.